PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma.

Short-term results from a recent trial suggest that reduced-dose chemoradiotherapy may achieve high local control with less ...

Author Julia DeVillers was daignosed with anal cancer and as it progresses, she was told she had 48 hours to live. Her ...

FDA approves Zynyz for advanced anal cancer, marking a breakthrough for the 10,000 diagnosed annually—including actress ...

With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an ...

A kinder treatment for anal cancer involving a lower dose and shorter course of radiotherapy is more effective than ...

Patients and clinicians have welcomed the results of the ACT4 PLATO trial, which was the first clinical trial in the world to ...

FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

A recent study presented at Digestive Disease Week 2025 reveals a concerning rise in anal cancer cases, particularly among ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

These findings highlight specific patient groups who may benefit from targeted screening for anal HPV and anal cancer,” said lead study author Dr. Ashley Robinson.